Regeneron REGN

Regeneron Pharmaceuticals is facing significant financial difficulties, with projections indicating a 66.9% decline in year-over-year earnings expected at $8.53 per share alongside revenues of about $2.76 billion. Despite promising developments in drug studies and collaborations, including a focus on CIDEB alongside Alnylam Pharmaceuticals, uncertainty looms over their leading products, Eylea and Dupixent, due to shifting regulatory landscapes. These challenges come in the wake of earlier struggles, including a sharp decline in share price and disappointing trial results, impacting investor confidence and expectation of future performance.